Patents by Inventor Marc Payton

Marc Payton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF AMG 900 FOR THE TREATMENT OF CANCER
    Publication number: 20150079022
    Abstract: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.
    Type: Application
    Filed: November 20, 2014
    Publication date: March 19, 2015
    Inventors: Gregory FRIBERG, Marc PAYTON
  • Use of AMG 900 for the treatment of cancer
    Patent number: 8921367
    Abstract: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: December 30, 2014
    Assignee: Amgen Inc.
    Inventors: Gregory Friberg, Marc Payton
  • Use of AMG 900 for the Treatment of Cancer
    Publication number: 20130323198
    Abstract: The present invention relates to methods of using AMG 900, a small molecule pan aurora kinase inhibitor, for the treatment of cancer, including solid tumors, hematologically derived tumors and the like. The invention further provides pharmaceutical compositions, dosage ranges and treatment regimens for administering AMG 900 to treat cancer.
    Type: Application
    Filed: May 30, 2013
    Publication date: December 5, 2013
    Inventors: Gregory FRIBERG, Marc PAYTON
  • Use Of N-(4-((3-(2-Amino-4-Pyrimidinyl)-2-Pyridinyl)Oxy)Phenyl)-4-(4-Methyl-2-Thienyl)-1-Phthalazinamine In The Treatment Of Antimitotic Agent Resistant Cancer
    Publication number: 20120028917
    Abstract: The present invention relates to methods of using the compound, N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl) -1-phthalazinamine, to treat cancers, including solid tumors, which have become resistant to treatment with chemotherapeutic agents, including anti-mitotic agents such as taxanes, and/or other anti-cancer agents, including aurora kinase inhibiting agents. The invention also includes methods of treating cancers refractory to such treatments by administering a pharmaceutical composition, comprising the compound to a cancer subject.
    Type: Application
    Filed: September 9, 2010
    Publication date: February 2, 2012
    Applicant: Amgen Inc.
    Inventors: Marc PAYTON, Richard KENDALL
  • Novel Cdk11 molecules and uses thereof
    Publication number: 20080050734
    Abstract: The present invention relates to a novel serine threonine kinase. The invention also relates to vector, host cells, antibodies and recombinant methods for producing the Cdk11 polypeptide. In addition, the invention discloses therapeutic, diagnostic and research utilities for Cdk11 and related products.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 28, 2008
    Applicant: AMGEN INC.
    Inventors: Steven Coats, Peter Yakowec, Marc Payton